Pieris Pharma

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ault Global Holdings

ReTo Eco-Solutions

Investing in penny stocks in June? Check these 3 out today The post Hot Penny Stocks to Buy?

Hot Penny Stocks to Buy? 3 For Your Morning Watchlist

Cinedigm

LAIX Inc - ADR

Zomedica

Best Robinhood penny stocks for Summer 2021? Check these 4 out The post 4 Robinhood Penny Stocks to Watch in Summer 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Robinhood Penny Stocks to Watch in Summer 2021

Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. The post PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today appeared first on InvestorPlace.

PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Today

Investors need to pay close attention to Pieris (PIRS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Pieris (PIRS) Stock?

Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) on Tuesday surged by over 100% after the company announced a respiratory and ophthalmology collaboration with Genentech. Shares are also trading higher this morning.

Where Will The Pieris Pharmacuetical Stock Rally End?

Protagenic Therapeutics

Sesen Bio Inc.

T2 Biosystems

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

Best Biotech Penny Stocks in June 2021? Check These 4 Out

The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by 103.24% yesterday. This is why it happened.

PIRS Stock Price: 103.24% Increase Explanation

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboration with Roche Holding AG's Genentech that could be valued at more than $1.4 billion. Trading volume spiked to a record 205.7 million shares, enough to make the stock the most actively traded on major U.S. exchanges, and compared with the full-day average of about 576,200 shares, according to FactSet.

Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billion

GT Biopharma Inc

Heron Therapeutics

Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?

Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are trading higher by 57% at $2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics.

What's Going On With Pieris Pharmaceuticals Stock Today?

The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by over 30% pre-market. This is why it happened.

PIRS Stock Price: Over 30% Increase Pre-Market Explanation

Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs BOSTON, MA / ACCESSWIRE / May 25, 2 021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced it has entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris' proprietary Anticalin® technology. The research collaboration will enable Pieris to combine its robust discovery engine with Genentech's targets, as well as its preclinical and clinical development expertise, to create novel therapies for the treatment of respiratory and ophthalmological diseases.

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech

BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management is scheduled to participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 1:00 PM EDT. A webcast of the company's presentation will be available at this link.

Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q1 2021 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 58.82% and 141.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.07), which beat the estimate of ($0.17).

Pieris Pharmaceuticals: Q1 Earnings Insights

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to receive $10 million upfront payment and is eligible to receive up to approximately $353 million in milestone payments , as well as tiered royalties and sublicense revenue share BOSTON, MA / ACCESSWIRE / May 17, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the first quarter of 2021 ended March 31, 2021 and provided an update on the Company's recent and anticipated future developments. "The last few months were marked by significant accomplishments.

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

Earnings Preview: Pieris Pharmaceuticals

BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2021 investor call on Monday, May 17, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call.

Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021

The stock price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) increased by over 5% pre-market. This is why it happened.

PIRS Stock: Over 5% Increase Pre-Market Explanation

Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the investigational new drug (IND)-enabling stage BOSTON and CAMBRIDGE, MA / ACCESSWIRE / April 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) and Boston Pharmaceuticals today announced that the companies have entered into an exclusive product license agreement to develop PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342.

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population ​including "cold" and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344/S095012 preclinical data show that the drug candidate induces a dose-dependent anti-tumor response in an anti-PD-L1-resistant mouse model BOSTON, MA / ACCESSWIRE / April 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today presented a clinical data update from the phase 1 monotherapy study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 bispecific for the treatment of HER2-expressing solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Virtual Congress 2021. The Company also presented preclinical data for PRS-344/S095012, a 4-1BB/PD-L1 bispecific the Company is developing with Servier, at a poster session at the congress.

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q4 2020 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -8.33% and -50.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Misses Revenue Estimates

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 5.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% over the past year to ($0.26), which missed the estimate of ($0.24).

News for Pieris Pharma Stock (PIRS)